Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 81,224	$ 194,905
Short-term investments	1,414,448	1,140,445
Accounts receivable	41,205	43,213
Inventory	13,720	11,381
Advance payments to contract manufacturers	13,015	26,450
Other current assets	15,212	21,293
Total current assets	1,578,824	1,437,687
Long-term investments	231,082	582,889
Property, plant and equipment, net	64,614	48,851
Operating lease right-of-use assets	134,888	0
Goodwill	76,501	76,501
Other assets	2,385	4,244
Total assets	2,088,294	2,150,172
Current liabilities:
Accounts payable	21,963	5,854
Accrued compensation	23,101	9,937
Accrued clinical trial expenses	38,338	14,700
Accrued contract manufacturing expenses	8,646	23,841
Other accrued expenses	11,394	9,580
Interest payable	4,198	4,198
Operating lease liabilities, current portion	9,318	0
Deferred revenue, current portion	8,392	13,892
Total current liabilities	125,350	82,002
Senior secured notes, net	248,257	246,950
Operating lease liabilities, less current portion	145,099	0
Liability related to the sale of future royalties, net	73,455	82,911
Deferred revenue, less current portion	6,779	10,744
Other long-term liabilities	643	9,990
Total liabilities	599,583	432,597
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at September 30, 2019 or December 31, 2018	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 175,786 shares and 173,530 shares outstanding at September 30, 2019 and December 31, 2018, respectively	17	17
Capital in excess of par value	3,241,160	3,147,925
Accumulated other comprehensive loss	(1,186)	(6,316)
Accumulated deficit	(1,751,280)	(1,424,051)
Total stockholders’ equity	1,488,711	1,717,575
Total liabilities and stockholders’ equity	$ 2,088,294	$ 2,150,172